Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Similar articles for PubMed (Select 8274361)

1.

Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis.

Stendig-Lindberg G, Tepper R, Leichter I.

Magnes Res. 1993 Jun;6(2):155-63.

PMID:
8274361
4.

Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.

Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L.

Rheumatol Int. 2005 Dec;26(2):157-61. Epub 2005 Jan 20.

PMID:
15660234
5.

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.

Osteoporos Int. 2003 Sep;14(9):741-9. Epub 2003 Jun 19.

PMID:
12827224
6.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
8.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
9.

The effect of alendronate in the treatment of postmenopausal osteoporosis.

Rozkydal Z, Janicek P.

Bratisl Lek Listy. 2003;104(10):309-13.

PMID:
15055730
10.

Prolonged magnesium deficiency causes osteoporosis in the rat.

Stendig-Lindberg G, Koeller W, Bauer A, Rob PM.

J Am Coll Nutr. 2004 Dec;23(6):704S-11S.

PMID:
15637219
11.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
12.

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, et al.

Bone. 1995 Oct;17(4):383-90.

PMID:
8573412
14.

Clodronic acid in the treatment of postmenopausal osteoporosis.

Tanakol R, Yarman S, Bayraktaroglu T, Boztepe H, Alagöl F.

Clin Drug Investig. 2007;27(6):419-33.

PMID:
17506592
15.

Strontium ranelate: a new paradigm in the treatment of osteoporosis.

Reginster JY, Deroisy R, Jupsin I.

Drugs Today (Barc). 2003 Feb;39(2):89-101. Review.

PMID:
12698204
17.

The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.

Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.

Osteoporos Int. 1997;7(1):52-8.

PMID:
9102064
18.

A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.

Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.

Acta Orthop Scand Suppl. 1997 Oct;275:108-11.

PMID:
9385282
19.

Effects of Alendronate on bone mass in women with osteoporosis.

Pilipović N, Branković S, Vujasinović-Stupar N.

Med Pregl. 2006 Sep-Oct;59(9-10):427-35. English, Serbian.

PMID:
17345818
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk